Company: PCRX
Filing Date: 2025-04-17
Form Type: DEFA14A
Source: 0001104659-25-036098
Chunk: 4

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-17
Form: DEFA14A
Chunk 4
---
 will cause its views to change. Except as required by applicable law, Pacira undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and readers should not rely on these forward-looking statements as representing Pacira’s views as of any date subsequent to the date of this document.

These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Pacira’s actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these statements. These factors include the matters discussed and referenced in the “Risk Factors” of Pacira’s most recent Annual Report on Form 10-K and in other filings that Pacira periodically makes with the SEC.

Important Additional Information Regarding Proxy Solicitation

Pacira intends to file a proxy statement and BLUE proxy card with
the U.S. Securities and Exchange Commission (the “SEC”) in connection with its solicitation of proxies for Pacira’s
2025 annual meeting of stockholders (the “2025 Proxy Statement,” and such meeting the “2025 Annual Meeting”).
BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS OF PACIRA ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED
TO THE SEC, INCLUDING PACIRA’S DEFINITIVE PROXY STATEMENT AND ANY AMENDMENTS AND SUPPLEMENTS THERETO, BECAUSE THEY WILL CONTAIN
IMPORTANT INFORMATION. These documents, including the definitive 2025 Proxy Statement (and any amendments or supplements thereto) and
other documents filed by Pacira with the SEC, are, or will be when filed, available for no charge on the SEC’s website at
and on Pacira’s investor relations website at .

Participants in the Solicitation

Pacira, its directors, director nominees, certain of its executive
officers and other employees may be deemed participants in the solicitation of proxies from stockholders in respect of the 2025 Annual
Meeting. Information regarding the names of Pacira’s directors and executive officers and their respective interests in Pacira
by security holdings or otherwise is set forth in Pacira’s proxy statement for the 2024 Annual Meeting of stockholders, filed with
the SEC on April 22, 2024
(the “2024 Proxy Statement”). Please refer to the sections captioned “Director Compensation,” “Executive
Compensation,” and “Stock Ownership Information” in the